Bio-Rad Laboratories Class A

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell BIO and other ETFs, options, and stocks.

About BIO

Bio-Rad Laboratories, Inc. engages in the development, manufacturing, and marketing of a portfolio of instruments, systems, reagents, and consumables. It operates through the following segments: Life Science and Clinical Diagnostics. 

CEO
Norman D. Schwartz
CEONorman D. Schwartz
Employees
7,450
Employees7,450
Headquarters
Hercules, California
HeadquartersHercules, California
Founded
1952
Founded1952
Employees
7,450
Employees7,450

BIO Key Statistics

Market cap
9.44B
Market cap9.44B
Price-Earnings ratio
43.04
Price-Earnings ratio43.04
Dividend yield
Dividend yield
Average volume
260.64K
Average volume260.64K
High today
$356.49
High today$356.49
Low today
$349.51
Low today$349.51
Open price
$355.97
Open price$355.97
Volume
156.15K
Volume156.15K
52 Week high
$365.00
52 Week high$365.00
52 Week low
$236.73
52 Week low$236.73

Stock Snapshot

Bio-Rad Laboratories Class A(BIO) stock is priced at $349.51, giving the company a market capitalization of 9.44B. It carries a P/E multiple of 43.04.

During the trading session on 2026-08-18, Bio-Rad Laboratories Class A(BIO) shares reached a daily high of $356.49 and a low of $349.51. At a current price of $349.51, the stock is 0.0% higher than the low and still -2.0% under the high.

Trading activity shows a volume of 156.15K, compared to an average daily volume of 260.64K.

Over the past 52 weeks, Bio-Rad Laboratories Class A(BIO) stock has traded between a high of $365.00 and a low of $236.73.

Over the past 52 weeks, Bio-Rad Laboratories Class A(BIO) stock has traded between a high of $365.00 and a low of $236.73.

BIO News

TipRanks 1d
Bio‑Rad Laboratories Balances Recovery And Headwinds In Q2

Bio-Rad Laboratories ((BIO)) has held its Q2 earnings call. Read on for the main highlights of the call. Summer Sale - Claim 70% Off TipRanks Unlock powerful in...

Simply Wall St 5d
Bio-Rad’s Restructuring and Digital PCR Momentum Might Change The Case For Investing In BIO

In early August 2026, Bio-Rad Laboratories reported second-quarter 2026 results showing sales of US$651.0 million, higher net income of US$371.4 million, and re...

Bio-Rad’s Restructuring and Digital PCR Momentum Might Change The Case For Investing In BIO

Analyst ratings

57%

of 7 ratings
Buy
28.6%
Hold
57.1%
Sell
14.3%

People also own

Based on the portfolios of people who own BIO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.